STATEMENT OF TRANSLATIONAL RELEVANCE
Ibrutinib, as well as other BCR-directed kinase inhibitors, leads to a transient, treatment-induced lymphocytosis. The increase in CLL cells in the blood develops within hours of the first drug dose due to an efflux of cells out of the lymphoid tissues. Given that redistributionlymphocytosis is a characteristic observation when treating CLL with ibrutinib, we sought to better understand the underlying biological mechanism by evaluating the in vivo effect of ibrutinib on the ability of CLL cells to migrate and adhere to stromal cells and components of the extracellular matrix. While we found an overall reduction in both migration and adhesion, only the ability of CLL cells to adhere to fibronectin was rapidly and almost completely inhibited by ibrutinib in all patients evaluated. The adhesion defect induced by ibrutinib was VLA-4 dependent, providing a mechanistic explanation for the treatment-induced lymphocytosis and suggesting a role for ibrutinib in disrupting CD49d-dependent pro-survival signals. 
INTRODUCTION
CLL is a malignancy of mature auto-reactive B-cells (1, 2) . The tumor microenvironment in secondary lymphoid tissues and the bone marrow plays a key role in the pathogenesis of the disease (3) (4) (5) . This is underscored by the observation that CLL cells undergo apoptosis in vitro unless surrogates of survival signals found in the tumor microenvironment are provided. Further, Herishanu et al. presented direct in vivo evidence that CLL cells are activated through the B-cell Receptor (BCR) in the lymph node microenvironment (4) . The BCR signaling pathway has emerged as a pivotal pathway in the pathogenesis of CLL and as a target for novel therapies (6) (7) (8) . Bruton's tyrosine kinase (BTK), a cytoplasmic TEC kinase, couples BCR activation to intracellular calcium release and NF-κB signaling (9) . BTK plays an essential role in B-cells as demonstrated by the severe defect in B-cell development due to loss of function mutations in this kinase in patients with X-linked agammaglobulinemia. Further, deletion of BTK in murine models supports a critical role for BTK in the development and progression of CLL (10, 11) .
Ibrutinib, an orally active covalent BTK inhibitor, was recently approved in the USA and Europe for the treatment of patients with CLL who have received at least one prior therapy as well as of previously-untreated patients who carry a deletion of chromosome band 17p13.1. Several clinical trials have shown that single-agent ibrutinib is well tolerated and can induce objective clinical responses in CLL; including in patients with high risk disease features (12) (13) (14) . Even as a single agent, ibrutinib induced durable responses in CLL patients with TP53 aberrations, including deletion 17p13.1 (del(17p)) and TP53 mutation, contrasting with the inferior responses and relatively early relapses when these high risk patients are treated with chemoimmunotherapy (14) . In a randomized phase 3 study of ibrutinib versus ofatumumab for relapsed or refractory CLL, patients treated with ibrutinib had a 78% reduction in the risk of tumor progression or death compared to patients in the ofatumumab arm (15) .
A transient increase in lymphocytosis is commonly observed when treatment with ibrutinib or other BCR-directed kinase inhibitors is initiated (13, 16) . In our investigator-initiated phase 2 study of ibrutinib in CLL, the average peak increase in the absolute lymphocyte count was greater than 65%, with more than 40% of patients reaching the peak on or before day 2 of therapy and 78% by day 28 (16) . Additionally, we found that the ibrutinib-induced increase in lymphocytosis, at least early on treatment, is due to the release of tumor cells from the tissue compartment into the peripheral blood (16) . This is considered to be an important drug effect as the microenvironment protects tumor cells from apoptosis through various stimuli such as chemokines, cytokines, and direct interactions with accessory cells and adhesion molecules (3, 17) . The hypothesis that ibrutinib, through a disruption of these tumor-microenvironment interactions, could sensitize the cells to cytotoxic or antibody therapy is currently being investigated in clinical trials.
In vitro studies with ibrutinib have demonstrated reductions in both CLL cell migration and adhesion; key mechanisms in the trafficking of cells between the peripheral blood and secondary lymphoid tissues. It has been previously shown that treatment with 1µM ibrutinib inhibits CLL cell chemotaxis toward the chemokines CXCL12, CXCL13 and CCL19 (18, 19).
Additionally, in vitro treatment with ibrutinib diminishes BCR-activated CLL cell adhesion to fibronectin and vascular cell adhesion molecule-1 (VCAM-1) (18). However, data on drug effects in vivo are limited. Within the microenvironment, integrins play a pivotal role in establishing contact of CLL cells with their surroundings and other cells (3, 17) . A molecule of central importance for these tumor-microenvironment interactions is CD49d (integrin α4) which heterodimerizes with CD29 (integrin β1) to form VLA-4 (20, 21). VLA-4 on CLL cells binds to fibronectin and VCAM-1 in the tissue compartments. CD49d is one of the most powerful prognostic markers in CLL; with high expression of CD49d on CLL cells identifying a more aggressive disease subset with inferior survival (22, 23). To characterize the in vivo drug effect on cell adhesion and migration we performed functional assays ex vivo using peripheral blood samples collected from CLL patients treated on an investigator-initiated phase 2 single agent ibrutinib trial.
Research. 
MATERIALS AND METHODS

Patient samples
This clinical trial of ibrutinib was registered at clinicaltrials.gov as NCT01500733. Patients with CLL or SLL who were either over the age of 65 or had TP53 aberrations were enrolled from December 2011 to January 2014. A total of 86 patients were enrolled, 30 of which were evaluated in this study. A few (n=4) untreated CLL patients enrolled on a natural history study (registered as NCT00923507 at clinicaltrials.gov) were also included in this study. For each set of analyses, 7-20 patients were evaluated; Supplementary Table S1 denotes which patients were analyzed in each experiment. Written informed consent was obtained in accordance with the Declaration of Helsinki, applicable federal regulations, and requirements of local institutional review boards. Peripheral blood samples were obtained pre-treatment (Pre) and on days 2 (after one dose of drug), 14, and 28 of ibrutinib treatment. Peripheral blood mononuclear cells (PBMCs) were isolated by density-gradient centrifugation (Ficoll Lymphocyte Separation Media; ICN Biomedicals) and viably frozen in 90% fetal bovine serum (FBS), 10% dimethyl sulfoxide (DSMO) (Sigma) in liquid nitrogen. Plasma supernatant from bone marrow aspirates was collected at baseline, prior to initiation of treatment. Clinical patient characteristics are summarized in Supplementary Table S2 .
Chemotaxis assay
Chemotaxis assays across polycarbonate Transwell inserts were performed as previously described (24). Briefly, 10 6 CLL PBMCs in AIM-V medium (Gibco) were transferred into the top chambers of Transwell culture inserts (Corning Incorporated) with a diameter of 6.5 mm and a pore size of 5 μm. Filters were then placed into wells containing medium (control), medium with 200 ng/mL CXCL12 and 100 ng/mL CCL19 (Prospec) or a mixture of 50% medium and 50% bone marrow supernatant collected pre-treatment. Where indicated, cells were pre-incubated with 1µM ibrutinib (Sellekchem) in vitro for 1 hour. CLL PBMCs were allowed to migrate for 3 hours at 37°C. Migrated cells in the lower chamber were collected, stained with CD19 and CD3
and counted using AccuCount blank particles (Spherotech) as previously described (25). The migration index was determined by subtracting the percent migration of the medium control from the percent migration of the chemotractant wells and normalizing. Migration experiments were performed in triplicate plates; results are reported as the average.
RESULTS
Ibrutinib inhibits migration of CLL cells
To determine the effect of ibrutinib on cellular migration in CLL PBMCs ex vivo, we used standard transwell migration assays. To validate our method respective to previously published in vitro data, we first evaluated the effect of in vitro treatment of CLL cells on migration towards two important chemokines, CXCL12 and CCL19, using, as in the previous reports, a dose of 1µM ibrutinib (18, 19). As expected, there was a modest but significant reduction in the migration of ibrutinib treated CLL cells towards the chemokine mixture (median change -33%, IQR: -2 to -59, n=12, P=0.04, Supplementary Fig. S1A ), although 3/12 patients did not show a reduction in cellular migration after ibrutinib treatment. In contrast, we did not observe a significant inhibition of T-cell migration (median change -8%, IQR: +24 to -21, n=12, P=0.28, Supplementary Fig. S1A ). We next evaluated the migratory ability of cells collected pretreatment compared to those collected from patients treated for 28 days with ibrutinib, the time point at which more than 75% of patients reached their peak ALC. This was done in all 12 patients evaluated in vitro, plus an additional three patients where samples were available (Supplemental Table S1 ). There was a significant reduction in migration of CLL cells obtained 
Ibrutinib inhibits CLL cell adhesion to fibronectin and stromal cells
To determine the effect of ibrutinib treatment on cell adhesion we chose a functional assay, utilizing fibronectin coated plates to model tumor-stromal interactions in the tissue microenvironment. We validated the performance of the assay using CFSE labeled PBMCs (CLL cell content 88-99%, Supplementary Table S4), either treated with 1µM ibrutinib or left untreated, and allowed them to adhere to a fibronectin-coated plate. After extensive washing, we quantified the number of adhered cells and found that there was a modest, but significant reduction in cell adhesion to fibronectin after ibrutinib treatment in vitro, confirming what has been previously reported (18) (median change -35%, IQR: -18 to -63, n=11, P=0.002, Supplementary Fig. S2A-B ).
Next we determined the effect of in vivo ibrutinib treatment using PBMCs collected from patients pre-treatment and after 28 days on ibrutinib. The percentage of CLL cells at all evaluated time points ranged from 88-99% (Supplementary Table S4 ). Figure 2A depicts representative microscopic images demonstrating the inability of CLL cells from patients treated with ibrutinib to adhere to fibronectin. This dramatic effect was seen in all patients evaluated (median change -98%, IQR: -91 to -100, n=13, P<0.001, Fig. 2B ). Because the onset of ibrutinib-induced lymphocytosis is virtually immediate and in many patients peaked within days (16), we also analyzed cells obtained after just one dose of ibrutinib (day 2). Even at this early time-point, adhesion was significantly reduced (median change -68%, IQR: -40 to -85, n=10, P= 0.002; Fig.   2C ) and was further reduced with continued treatment (n=8, Fig. 2D ). We again found that key prognostic markers could not account for the observed inter-patient variability (n=10, Supplementary Fig. S2C ). As fibronectin is only one of the many molecules that can facilitate adhesion, we repeated our analyses using the Hs5 stromal cell line. We again found that there was only a modest reduction in adhesion after ibrutinib treatment in vitro (median change -14%, IQR: -6 to -29, n=9, P=0.004, Supplementary Fig. S3A) ; with a more substantial reduction observed in cells obtained from patients after 28 days on ibrutinib (median change -20%, n=11, P=0.005, IQR: -5 to -30, Supplementary Fig. S3B-C) . In summary, treatment with ibrutinib consistently abrogated adhesion of CLL cells to fibronectin and significantly reduced their ability to adhere to stromal cells.
Ibrutinib treatment leads to a release of adhered cells
Having demonstrated that circulating CLL cells from the blood of patients being treated with ibrutinib have a defect in cell adhesion, we sought to determine whether ibrutinib could also detach CLL cells already firmly adhered to solid supports. To address this question, we evaluated CLL PBMCs collected pre-treatment and from untreated CLL patients enrolled on a natural history study (Supplemental Table S1 ). CLL PBMCs were allowed to adhere to fibronectin-coated plates overnight. The next day the plates were washed extensively to remove all cells not firmly attached, and then incubated with 1µM ibrutinib for 1 hour. Micrographs in Figure 3A show results of two representative experiments utilizing samples collected preibrutinib. Overall, there was a moderate, but uniform decrease in the number of adherent cells in plates treated with ibrutinib compared to controls (median change -17%, IQR: -6 to -27, n=11, Fig. 3B ). Conversely, treatment with ibrutinib lead to a significant increase in the number of cells released into the cell culture supernatant (median change +22%, IQR: +1 to +78, n=11, P=0.02, Fig. 3C ). Collectively, these data show that ibrutinib can detach and mobilize cells that are adhered to fibronectin; however, only a minor fraction of the total cells are being released.
P=0.002,
Ibrutinib modestly reduces expression of adhesion molecules that bind fibronectin
Next we sought to investigate the mechanisms responsible for the observed decrease in cellular adhesion on ibrutinib in a subset of patients. We first analyzed expression of the most common adhesion molecules known to bind to fibronectin. In particular, we evaluated CD44, which binds to the COOH-terminal heparin binding domain, and very late antigen-4 (VLA-4), a heterodimer of integrin α4 (CD49d) and integrin β1 (CD29), which binds to the IIICS (V) CS1 region and the EIIIA domain of fibronectin (27, 28). Baseline expression of these key integrins is summarized in Supplementary Table S3 . Figure 4A Fig. 4A ). This apparent discrepancy is due to the very high expression of CD44 at baseline so that even in samples with a substantial reduction, CD44 remained expressed on almost all CLL cells after treatment. The changes in expression of the adhesion molecules in individual patients are summarized in Figure 4 . In 12 of 20 patients (60%), CLL cells, obtained at baseline, expressed CD49d; of these, 7 (58%) showed a reduction on ibrutinib (Fig. 4B) . Similarly, CD29, expressed in all patients at baseline, decreased in 12 of 20 patients (60%) on treatment (Fig. 4C ). Lastly, the expression level of CD44 decreased in 10 of 19 evaluated patients (60%) after 28 days of in vivo ibrutinib treatment (Fig. 4D) . In summary, ibrutinib modestly reduced the expression of adhesion molecules; however this occurred in only a little more than half of the evaluated patients.
Adhesion of CLL cells is equally reduced by ibrutinib and VLA-4 blockade
As VLA-4 has been demonstrated to be a key molecule in facilitating binding to fibronectin, we tested the importance of VLA-4 for CLL cell adhesion using the small molecule α4β1-integrin antagonist firategrast. A dose titration of firategrast was performed from 100nM to 10µM; 500nM was determined to be the lowest optimal concentration for inhibition of CLL cell adhesion to fibronectin (data not shown). Treatment of CLL PBMCs with firategrast in vitro significantly reduced CLL cells adhesion to fibronectin (median change -32%, IQR: -13 to -44, n=15, Fig. 5A ). To further delineate if CD49d is the key alpha integrin important for CLL adhesion to fibronectin, we treated CLL PBMCs with blocking antibodies against integrin α4 and β1 separately. The blockade of integrin α4 (CD49d) inhibited cellular adhesion significantly (median change -23%, IQR: -10 to -60, n=11, P<0.001, Fig. 5B ), while the anti-integrin β1 (CD29) antibody had no consistent effect (Fig. 5B) . Notably, the degree of inhibition achieved with ibrutinib and anti-CD49d was highly correlated (R=0.90, n=11, P<0.001; Fig. 5C ). As a control we used a blocking antibody against integrin β2 (CD18), an adhesion molecule that does not bind fibronectin, and saw no effect (n=11, Supplementary Fig. S4 ). Thus, both CD49d and BTK are important for CLL cell adhesion and inhibition of either molecule inhibits adhesion of CLL cells to a similar degree. 
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DISCUSSION
Treatment-induced lymphocytosis, the transient increase in circulating tumor cells at the initiation of treatment of CLL patients with kinase inhibitors, is a hallmark of these targeted agents (13, 16, 32). As we previously reported, the onset of ibrutinib-induced lymphocytosis is virtually immediate and, at least initially, due to an efflux of cells from the lymph node into the peripheral blood (16) . In vitro ibrutinib can disrupt several survival pathways, including cell migration and adhesion that are important for tumor-microenvironment interactions (18, 19, 33 ).
Here we investigated the effects of ibrutinib in vivo by analyzing CLL cells obtained from patients treated with single agent ibrutinib. The most striking finding was that circulating CLL cells from patients having received ibrutinib for 28 days showed a near complete loss in their ability to adhere to fibronectin. Notably, this effect was ubiquitous, occurring in all samples studied, and already apparent after just one dose of drug, consistent with the timing of the lymphocytosis. Inhibition of cell adhesion appears to be a direct effect of ibrutinib as it manifested within hours of the first dose and was readily reversible in cells stimulated with PMA, which activates PKC independent of BTK (29, 31). While we also observed some reduction in the expression of the adhesion molecules CD29, CD44 and CD49d, these changes were minimal, did not occur in all patients and were only apparent at later time points, suggesting that down-modulation of adhesion molecules is not the primary reason for the observed adhesion defect. Additionally, we also demonstrated a reduction in cell migration in samples obtained after 28 days of ibrutinib treatment; however, this effect was more variable and not seen in all n.s.
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